PV QA 1 - Poster Viewing Q&A 1
Purpose/Objective(s)::While short-course radiation therapy (5x5Gy) is a widely tested regimen, Widder et al. introduced a modified regimen with a total dose of 25Gy given by a single fraction of 2.5Gy, delivered twice daily [British Journal of Cancer (2005) 92, 1209 – 1214]. Due to the lower single fraction dose compared to the standard regimen, the modified regimen may have better long term tolerability. The evaluation of the efficacy and the safety of this short course hyperfractionated accelerated radiation therapy (SC-HART) at our institution is presented.
Materials/Methods:We retrospectively evaluated the data of 251 Patients treated with SC-HART from 2002 until 2017. All patients had clinical stage UICC II-III rectal cancer and were treated with 25Gy in 2.5Gy single fractions twice daily. Patients were intended for surgical treatment within 1 week of SC-HART. This report focuses on the patients that received surgery within 1 week of RT. The primary outcomes were locoregional control (LC), freedom from distant metastasis (DM) and overall survival (OS) (Kaplan-Meier) as well as acute toxicities. An analysis of long term toxicities will be added in a cross-sectional study and presented later.
Results:The median age of the patients treated with surgery was 70.7 (37.6-94.1) years. Median follow-up of survivors was 108.7 months. 98 (39%) patients had stage II, 153 (61%) patients stage III disease. 13 (5.2%) patients experienced a local recurrence and the median time to local recurrence was 33.1 months. There were no toxicities grade II or higher reported during the SC-HART. The 5-year and 10-year local control, freedom from DM and OS were 95.3%, 94.1%; 89.2%, 87.7% and 71.8%, 57.0%, respectively.
Conclusion:SC-HART is an effective and well tolerated regime in patients with rectal cancer and poses an alternative for the standard fractionated short-course Treatment.
The asset you are trying to access is locked. Please enter your access key to unlock.